|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main outcomes selected for GRADE analysis were clinical remission at week 8 (Crohn's Disease Activity Index [CDAI] ≤150), clinical response at week 8 (CDAI reduction ≥ 100 or clinical remission), and serious adverse events.
|
31476018 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patients with moderate-to-severe active CD had a statistically significant higher value of CDAI and hsCRP concentrations compared to those being in the asymptomatic remission or at the mildly active stage of the disease.
|
31646581 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150).
|
30727745 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyses of efficacy using Crohn's Disease Activity Index [CDAI] endpoints [remission, clinical response [CR]-70, CR-100, patient-reported outcome [PRO] remission] or Harvey-Bradshaw Index [HBI] endpoints [remission/response] were conducted for induction and maintenance treatment periods.
|
30753371 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn's Disease Activity Index (CDAI > 150)] were included.
|
31598133 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients who achieved clinical response (defined as delta Crohn's disease activity index [CDAI] > 70 and CDAI < 200) at 10-14 weeks after the start of infliximab or adalimumab were included.
|
29935082 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Disease activity was assessed by Harvey-Bradshow Crohn's disease activity index(Harvey-Bradshow CDAI).
|
30278183 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary outcome was clinical remission (Crohn's disease activity index [CDAI]<150, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing.
|
29788260 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients who did not achieve deep remission, defined as clinical remission (Crohn's Disease Activity Index [CDAI] <150) and endoscopic remission (Crohn's Disease Endoscopic Index of Severity [CDEIS] ≤4, or ≤2 for patients with isolated ileitis), at week 12 received open-label intravenous therapy with 600 mg risankizumab every 4 weeks for 12 weeks; patients in deep remission at week 12 entered a 12-week washout phase.
|
30056030 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy variables included clinical response (Crohn's Disease Activity Index [CDAI] decrease from baseline ≥70/≥100 points [CR-70/CR-100]) and remission [CDAI<150], steroid discontinuation and fistula remission [absence of drainage].
|
29697818 |
2018 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary outcome was clinical remission (Crohn's disease activity index [CDAI] < 150 or pediatric CDAI <10, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing.
|
29867171 |
2018 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
193/720 (27%) received anti-tubercular therapy which significantly contributed to diagnostic delay (OR: 2.47; 95% CI: 1.76-3.47, P < 0.001) with 47% showing initial clinical response (Crohn's disease activity index- CDAI decrease >100).
|
29572889 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
At Week 8, ustekinumab-treated responders (Crohn's Disease Activity Index [CDAI] reduction ≥100 or CDAI <150 points) were re-randomised to subcutaneous maintenance therapy [IM-UNITI, n = 388] with placebo, ustekinumab 90 mg every 12 weeks [q12w], or ustekinumab 90 mg every 8 weeks [q8w], for 44 additional weeks.
|
29726939 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary outcome for this analysis was 3-month steroid-free clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150).
|
28497755 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-three adult small-bowel CD patients in clinical remission (Crohn's Disease Activity Index [CDAI] <150) were prospectively enrolled at 4 academic centers and followed clinically for 12 months.
|
28947363 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inflammatory activity of UC was assessed by Mayo score and of CD by CDAI and SES-CD scoring systems.
|
29550798 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary endpoint was the rate of clinical remission [Crohn's Disease Activity Index [CDAI] < 150] at end of treatment, ie at Week 12 or withdrawal.
|
27707789 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mayo Clinic Score [MCS] or Crohn's Disease Activity Index [CDAI], most frequently used as end points in conventional clinical trials, are composite instruments that are not fully objective nor capture the impact of disease from the patient's perspective.
|
27797917 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission.
|
27930408 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 6 months, 70% of patients achieved drug-free clinical remission (Crohn's Disease Index of Severity [CDAI] < 150).
|
28419282 |
2017 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effectiveness and toxicity defined by time to response CD activity index (CDAI <150, +/- steroids) or time to sustained response (CDAI <150, off steroids x 8 wk) and reduction in leukopenic events, respectively.
|
16181376 |
2005 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SNPs were genotyped (TaqMan) in two cohorts ( n= 90 and n= 444 (ACCENT I)) of active Crohn's disease patients (CDAI 220-450).
|
12360101 |
2002 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the end of treatment.47% (7 of 15) of ISIS 2302-treated and 20% (1 of 5) of the placebo-treated patients were in remission (Crohn's Disease Activity Index [CDAI] < 150).
|
9609749 |
1998 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with active CD of the terminal ileum (CD activity index, CDAI, > 150; n = 14), patients with CD in remission (CDAI < 150 n = 10), first-degree relatives of the CD patients (n = 21) and healthy controls (n = 43) were orally intubated with a catheter allowing occlusion and perfusion of a segment of the proximal jejunum.
|
1426699 |
1992 |